Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Phase 4

Active, not recruiting

Conditions: Acute Myocardial Infarction
Non-ST Elevation Myocardial Infarction (nSTEMI)
ST Elevation Myocardial Infarction

Interventions: Drug: Metoprolol Succinate
Drug: Bisoprolol
Drug: Carvedilol
Drug: Nebivolol

First Posted Date: 2018-12-19

Last Posted Date: 2024-12-11

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 2760

Registration Number: NCT03778554

Locations: 🇩🇰
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23, Copenhagen, Denmark

Beta-blockers for Oesophageal Varices

Phase 4

Recruiting

Conditions: Cirrhoses, Liver
Oesophageal Varices

Interventions: Drug: Carvedilol

First Posted Date: 2018-12-17

Last Posted Date: 2019-10-03

Lead Sponsor: King's College Hospital NHS Trust

Target Recruit Count: 1200

Registration Number: NCT03776955

Locations: 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Royal London Hospital (Barts), London, United Kingdom
🇬🇧
King's College Hosptial NHS Foundation Trust (Denmark Hill), London, United Kingdom

and more 1 locations

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

Phase 2

Recruiting

Conditions: Symptomatic Parkinson Disease
Pre-motor Parkinson Disease
REM Sleep Behavior Disorder

Interventions: Drug: Carvedilol

First Posted Date: 2018-12-13

Last Posted Date: 2024-01-12

Lead Sponsor: Michele Tagliati, MD

Target Recruit Count: 15

Registration Number: NCT03775096

Locations: 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States

Carvedilol for Prevention of Esophageal Varices Progression

Not Applicable

Conditions: Cirrhosis, Liver
Portal Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2018-11-09

Last Posted Date: 2022-12-01

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 240

Registration Number: NCT03736265

Locations: 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

and more 3 locations

Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension

Phase 2

Conditions: Cirrhosis
Portal Hypertension
Variceal Hemorrhage

Interventions: Drug: Propranolol
Drug: Carvedilol
Drug: Rosuvastatin
Drug: Placebo

First Posted Date: 2018-10-25

Last Posted Date: 2019-05-14

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 80

Registration Number: NCT03720067

Locations: 🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Phase 4

Conditions: Outflow Tract
Ventricular Premature Complexes
Carvedilol

Interventions: Drug: Carvedilol
Drug: Flecainide

First Posted Date: 2018-07-16

Last Posted Date: 2018-07-18

Lead Sponsor: Keimyung University Dongsan Medical Center

Target Recruit Count: 104

Registration Number: NCT03587558

Locations: 🇰🇷
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Severance Cardiovascular Hospital, Seoul, Korea, Republic of

and more 8 locations

Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

Phase 3

Conditions: Chemotherapy Related Cardiac Dysfunction

Interventions: Drug: Carvedilol

First Posted Date: 2018-05-31

Last Posted Date: 2018-05-31

Lead Sponsor: Makerere University

Target Recruit Count: 50

Registration Number: NCT03542058

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Phase 3

Recruiting

Conditions: Stage IV Breast Cancer AJCC v6 and v7
Recurrent Breast Carcinoma
HER2/Neu Positive
Metastatic Malignant Neoplasm in the Brain
Cardiotoxicity

Interventions: Other: Laboratory Biomarker Analysis
Drug: Carvedilol
Other: Patient Observation

First Posted Date: 2018-02-01

Last Posted Date: 2024-04-12

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 817

Registration Number: NCT03418961

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States

and more 587 locations